Clinical trial
Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With…
NCT00149006 · Hadassah Medical Organization, Other · Unknown status
Key facts
| NCT number | NCT00149006 |
|---|---|
| Title | Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors |
| Official title | Tumor-Selective and Systemic Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With rIL-2 and Non-Myeloablative Stem Cell Transplantation |
| Lead sponsor | Hadassah Medical Organization, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Procedure |
| Interventions | Cell therapy |
| Enrollment | 100 |
| Start date | Dec 1, 1996 |
| First posted | Sep 8, 2005 |
| Last update posted | Mar 14, 2007 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: